Gut and Gastroenterology

Abstract

Administration of Nalfurafine Hydrochloride in Patients with Hepatocellular Carcinoma and Refractory Pruritus Improved Patient-Reported Outcome

Author(s): Toru Ishikawa, Hiroshi Hirosawa

Background: Patients with hepatocellular carcinoma (HCC) frequently suffer from pruritus, which can severely impair their health-related quality of life (HRQOL). Nalfurafine hydrochloride, a selective κ-opioid receptor agonist, was recently approved in Japan for refractory pruritus in patients with chronic liver diseases, but it still remains unclear whether this treatment improves the patient-reported outcome (PRO) in HCC patients with refractory pruritus. Herein, we conducted a study to investigate the efficacy of nalfurafine hydrochloride in terms of PRO.
Methods: We identified 21 chronic liver disease patients with pruritus after screening for pruritus. The participants received 2.5 μg nalfurafine hydrochloride once daily. Generic HRQOL using short form 36 (SF-36) and the visual analog scale (VAS) were also measured at baseline and at end of treatment.
Results: VAS significantly declined during the study period, from 43.7 ± 34.1 to 14.3 ± 23.8 (p = 0.002) at bedtime between baseline and end of treatment, respectively, indicating a significant effect of nalfurafine hydrochloride. In HCC group, the mean VAS at baseline and at end of treatment was 46.8 ± 35.3 and 13.0 ± 19.4, respectively, representing a more pronounced reduction (p = 0.009) at bednight. Furthermore, the mean VAS at baseline and at end of treatment was 31.1 ± 31.7 and 6.6 ± 8.2, respectively, representing a more pronounced reduction (p = 0.042) at upon awaking. Vitality (VT) and mental health (MH) improved in overall chronic liver disease patients undergoing this therapy. VT domains of SF-36 was significantly altered by this treatment in HCC group (p=0.045).
Conclusions: This study demonstrated that nalfurafine hydrochloride improved pruritus in chronic liver disease patients, and more effective on the PRO in chronic liver disease patients with HCC.


Mission and Vision Membership Withdrawal Policy Submit Paper Publication ethics
Creative Commons License This work is licensed under a Creative Commons Attribution 4.0 International License © 2018 sciaeon.org